Viridian Therapeutics, Inc.\DE Q3 2026 Results: Net Loss of $101M, Loss Widens
Viridian Therapeutics is transitioning toward commercialization with the submission of a Marketing Authorization Application for veligrotug in Europe and a planned BLA submission for elegrobart in early 2027. The company remains pre-profit, relying on existing cash and anticipated future revenues to fund its clinical pipeline, including new trials for VRDN-292 and its FcRn inhibitor portfolio.
- Key figure
- Net loss $101M